Development and Biological Activity of Long-acting Recombinant Human Interferon-α2b

Overview

Journal BMC Biotechnol

Publisher Biomed Central

Specialty Biotechnology

Date 2020 Mar 15

PMID 32169063

Citations 4

Authors

Qian Zhang

Chao Wang

Fenlian Ma

Lihong Yao

Hanchun Gao

Luyan Zhu

Lishu Zheng

Affiliations

Soon will be listed here.

Abstract

Background: The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects. However, because the half-life of IFN is short, its clinical application is limited. Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.

Results: Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b. They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b). Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively. The proteins were purified with affinity chromatography and molecular sieve chromatography. IFN-1CTPON and IFN-2CTPON showed antiviral and antiproliferative activities in vitro. Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.

Conclusions: CHO cell strains stably expressing long-acting rhIFN-α2b were screened. The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.

Citing Articles

Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals.

Gimeno A, Ehlers A, Delgado S, Langenbach J, van den Bos L, Kruijtzer J J Am Chem Soc. 2024; 146(50):34452-34465.

PMID: 39653378 PMC: 11664507. DOI: 10.1021/jacs.4c11091.

Meta-analysis of the effect and safety of recombinant human interferon α-2b combined with Baofukang suppository in the treatment of HPV infection.

He C, Song C, Li M, Ma W, Sun S Am J Transl Res. 2022; 14(11):7632-7642.

PMID: 36505291 PMC: 9730096.

Recent and future perspectives on engineering interferons and other cytokines as therapeutics.

Aung T, Grubbe W, Nusbaum R, Mendoza J Trends Biochem Sci. 2022; 48(3):259-273.

PMID: 36241490 PMC: 9974544. DOI: 10.1016/j.tibs.2022.09.005.

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

Kaseb A, Hasanov E, Tran Cao H, Xiao L, Vauthey J, Lee S Lancet Gastroenterol Hepatol. 2022; 7(3):208-218.

PMID: 35065057 PMC: 8840977. DOI: 10.1016/S2468-1253(21)00427-1.

References

Ceaglio N, Etcheverrigaray M, Conradt H, Grammel N, Kratje R, Oggero M . Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. J Biotechnol. 2010; 146(1-2):74-83. DOI: 10.1016/j.jbiotec.2009.12.020. View

Furuhashi M, Shikone T, Fares F, Sugahara T, Hsueh A, Boime I . Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG) beta-subunit to the common alpha-subunit: retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG. Mol Endocrinol. 1995; 9(1):54-63. DOI: 10.1210/mend.9.1.7539107. View

Li S, Gong M, Zhao F, Shao J, Xie Y, Zhang Y . Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Cell Physiol Biochem. 2018; 51(5):2377-2396. DOI: 10.1159/000495897. View

Lu X, Wang J, Jin X, Zhu J . High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo. BMC Biotechnol. 2015; 15:54. PMC: 4464711. DOI: 10.1186/s12896-015-0177-1. View

Bonetti A, Kim S . Pharmacokinetics of an extended-release human interferon alpha-2b formulation. Cancer Chemother Pharmacol. 1993; 33(3):258-61. DOI: 10.1007/BF00686225. View

Yuan W, Zhang W, Ma F, Li J, Zhang Q, Zheng L . IFN-λ1 in CHO cells: its expression and biological activity. Cell Mol Biol Lett. 2017; 22:26. PMC: 5709978. DOI: 10.1186/s11658-017-0057-x. View

Fares F, Suganuma N, Nishimori K, Lapolt P, Hsueh A, Boime I . Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992; 89(10):4304-8. PMC: 49070. DOI: 10.1073/pnas.89.10.4304. View

Kotenko S, Gallagher G, Baurin V, Lewis-Antes A, Shen M, Shah N . IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2002; 4(1):69-77. DOI: 10.1038/ni875. View

Podobnik B, Helk B, Smilovic V, Skrajnar S, Fidler K, Jevsevar S . Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate. Bioconjug Chem. 2015; 26(3):452-9. DOI: 10.1021/bc500523t. View

10.

Mangan N, Fung K . Type I interferons in regulation of mucosal immunity. Immunol Cell Biol. 2012; 90(5):510-9. DOI: 10.1038/icb.2012.13. View

11.

Khan M, Hassan N, Ahmad N, Khan M, Zafar A, Khan F . Studies to analyse the relationship between IFNα2b gene dosage and its expression, using a Pichia pastoris-based expression system. Yeast. 2013; 31(1):13-28. DOI: 10.1002/yea.2990. View

12.

Nelson D, Rustgi V, Balan V, Sulkowski M, Davis G, Muir A . Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol. 2008; 7(2):212-8. DOI: 10.1016/j.cgh.2008.10.035. View

13.

Youngster S, Wang Y, Grace M, Bausch J, Bordens R, Wyss D . Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des. 2002; 8(24):2139-57. DOI: 10.2174/1381612023393242. View

14.

Zeuzem S, Sulkowski M, Lawitz E, Rustgi V, Rodriguez-Torres M, Bacon B . Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010; 139(4):1257-66. DOI: 10.1053/j.gastro.2010.06.066. View

15.

Rodriguez M, Ceaglio N, Antuna S, Tardivo M, Etcheverrigaray M, Prieto C . High yield process for the production of active human α-galactosidase a in CHO-K1 cells through lentivirus transgenesis. Biotechnol Prog. 2017; 33(5):1334-1345. DOI: 10.1002/btpr.2538. View

16.

Peng F, Duan Z, Zheng L, Xie Z, Gao H, Zhang H . Purification of recombinant human interferon-epsilon and oligonucleotide microarray analysis of interferon-epsilon-regulated genes. Protein Expr Purif. 2007; 53(2):356-62. DOI: 10.1016/j.pep.2006.12.013. View

17.

Isaacs A, Lindenmann J . Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267. J Immunol. 2015; 195(5):1911-20. View

18.

Oya M, Asakura H, Mizuno R, Marumo K, Murai M . Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations. Biomed Res. 2005; 26(3):135-7. DOI: 10.2220/biomedres.26.135. View

19.

Gajewski T, Corrales L . New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015; 26(2):175-8. PMC: 4387009. DOI: 10.1016/j.cytogfr.2015.01.001. View

20.

Meller S, Gerber P, Kislat A, Hevezi P, Gobel T, Wiesner U . Allergic sensitization to pegylated interferon-α results in drug eruptions. Allergy. 2015; 70(7):775-83. DOI: 10.1111/all.12618. View